FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179600404> ?p ?o ?g. }

• W3179600404 abstract "MitoTracker Deep Red (MTDR) is a relatively non-toxic, carbocyanine-based, far-red, fluorescent probe that is routinely used to chemically mark and visualize mitochondria in living cells. Previously, we used MTDR at low nano-molar concentrations to stain and metabolically fractionate breast cancer cells into Mito-high and Mito-low cell sub-populations, by flow-cytometry. Functionally, the Mito-high cell population was specifically enriched in cancer stem cell (CSC) activity, i) showing increased levels of ESA cell surface expression and ALDH activity, ii) elevated 3D anchorage-independent growth, iii) larger overall cell size (&gt;12-μm) and iv) Paclitaxel-resistance. The Mito-high cell population also showed enhanced tumor-initiating activity, in an in vivo preclinical animal model. Here, we explored the hypothesis that higher nano-molar concentrations of MTDR could also be used to therapeutically target and eradicate CSCs. For this purpose, we employed an ER(+) cell line (MCF7) and two triple negative cell lines (MDA-MB-231 and MDA-MB-468), as model systems. Remarkably, MTDR inhibited 3D mammosphere formation in MCF7 and MDA-MB-468 cells, with an IC-50 between 50 to 100 nM; similar results were obtained in MDA-MB-231 cells. In addition, we now show that MTDR exhibited near complete inhibition of mitochondrial oxygen consumption rates (OCR) and ATP production, in all three breast cancer cell lines tested, at a level of 500 nM. However, basal glycolytic rates in MCF7 and MDA-MB-468 cells remained unaffected at levels of MTDR of up to 1 μM. We conclude that MTDR can be used to specifically target and eradicate CSCs, by selectively interfering with mitochondrial metabolism, by employing nano-molar concentrations of this chemical entity. In further support of this notion, MTDR significantly inhibited tumor growth and prevented metastasis in vivo , in a xenograft model employing MDA-MB-231 cells, with little or no toxicity observed. In contrast, Abemaciclib, an FDA-approved CDK4/6 inhibitor, failed to inhibit metastasis. Therefore, in the future, MTDR could be modified and optimized via medicinal chemistry, to further increase its potency and efficacy, for its ultimate clinical use in the metabolic targeting of CSCs for their eradication." @default.
• W3179600404 created "2021-07-19" @default.
• W3179600404 creator A5011871781 @default.
• W3179600404 creator A5016681558 @default.
• W3179600404 creator A5052869818 @default.
• W3179600404 creator A5061366926 @default.
• W3179600404 creator A5067681642 @default.
• W3179600404 date "2021-07-30" @default.
• W3179600404 modified "2023-10-16" @default.
• W3179600404 title "MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity In Vivo" @default.
• W3179600404 cites W1897724420 @default.
• W3179600404 cites W1978803910 @default.
• W3179600404 cites W1984414408 @default.
• W3179600404 cites W2009450454 @default.
• W3179600404 cites W2036456322 @default.
• W3179600404 cites W2044459219 @default.
• W3179600404 cites W2057896630 @default.
• W3179600404 cites W2086861031 @default.
• W3179600404 cites W2088671304 @default.
• W3179600404 cites W2105267564 @default.
• W3179600404 cites W2114388515 @default.
• W3179600404 cites W2136596688 @default.
• W3179600404 cites W2136679767 @default.
• W3179600404 cites W2145006425 @default.
• W3179600404 cites W2148060280 @default.
• W3179600404 cites W2150199541 @default.
• W3179600404 cites W2290812258 @default.
• W3179600404 cites W2438898883 @default.
• W3179600404 cites W2517430769 @default.
• W3179600404 cites W2574211880 @default.
• W3179600404 cites W2588515730 @default.
• W3179600404 cites W2599813635 @default.
• W3179600404 cites W2618608383 @default.
• W3179600404 cites W2636907163 @default.
• W3179600404 cites W2789925759 @default.
• W3179600404 cites W2790368179 @default.
• W3179600404 cites W2790406197 @default.
• W3179600404 cites W2790599519 @default.
• W3179600404 cites W2799425529 @default.
• W3179600404 cites W2885543523 @default.
• W3179600404 cites W2892978381 @default.
• W3179600404 cites W2897148138 @default.
• W3179600404 cites W2898192381 @default.
• W3179600404 cites W2904380187 @default.
• W3179600404 cites W2910972034 @default.
• W3179600404 cites W2911331376 @default.
• W3179600404 cites W2914493448 @default.
• W3179600404 cites W2946075767 @default.
• W3179600404 cites W2963980714 @default.
• W3179600404 cites W2979558848 @default.
• W3179600404 cites W2979967148 @default.
• W3179600404 cites W916516836 @default.
• W3179600404 doi "https://doi.org/10.3389/fonc.2021.678343" @default.
• W3179600404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8361836" @default.
• W3179600404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34395247" @default.
• W3179600404 hasPublicationYear "2021" @default.
• W3179600404 type Work @default.
• W3179600404 sameAs 3179600404 @default.
• W3179600404 citedByCount "9" @default.
• W3179600404 countsByYear W31796004042021 @default.
• W3179600404 countsByYear W31796004042022 @default.
• W3179600404 countsByYear W31796004042023 @default.
• W3179600404 crossrefType "journal-article" @default.
• W3179600404 hasAuthorship W3179600404A5011871781 @default.
• W3179600404 hasAuthorship W3179600404A5016681558 @default.
• W3179600404 hasAuthorship W3179600404A5052869818 @default.
• W3179600404 hasAuthorship W3179600404A5061366926 @default.
• W3179600404 hasAuthorship W3179600404A5067681642 @default.
• W3179600404 hasBestOaLocation W31796004041 @default.
• W3179600404 hasConcept C121608353 @default.
• W3179600404 hasConcept C1491633281 @default.
• W3179600404 hasConcept C150903083 @default.
• W3179600404 hasConcept C153911025 @default.
• W3179600404 hasConcept C185592680 @default.
• W3179600404 hasConcept C207001950 @default.
• W3179600404 hasConcept C28328180 @default.
• W3179600404 hasConcept C2908647359 @default.
• W3179600404 hasConcept C502942594 @default.
• W3179600404 hasConcept C54355233 @default.
• W3179600404 hasConcept C553184892 @default.
• W3179600404 hasConcept C55427017 @default.
• W3179600404 hasConcept C55493867 @default.
• W3179600404 hasConcept C71924100 @default.
• W3179600404 hasConcept C81885089 @default.
• W3179600404 hasConcept C86803240 @default.
• W3179600404 hasConcept C95444343 @default.
• W3179600404 hasConcept C96232424 @default.
• W3179600404 hasConcept C99454951 @default.
• W3179600404 hasConceptScore W3179600404C121608353 @default.
• W3179600404 hasConceptScore W3179600404C1491633281 @default.
• W3179600404 hasConceptScore W3179600404C150903083 @default.
• W3179600404 hasConceptScore W3179600404C153911025 @default.
• W3179600404 hasConceptScore W3179600404C185592680 @default.
• W3179600404 hasConceptScore W3179600404C207001950 @default.
• W3179600404 hasConceptScore W3179600404C28328180 @default.
• W3179600404 hasConceptScore W3179600404C2908647359 @default.
• W3179600404 hasConceptScore W3179600404C502942594 @default.
• W3179600404 hasConceptScore W3179600404C54355233 @default.
• W3179600404 hasConceptScore W3179600404C553184892 @default.
• W3179600404 hasConceptScore W3179600404C55427017 @default.

• next